BCM
BML Capital Management Portfolio holdings
AUM
$131M
This Quarter Return
-2%
1 Year Return
+89.45%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$108M
AUM Growth
+$108M
(-2.4%)
Cap. Flow
+$5.28M
Cap. Flow
% of AUM
4.87%
Top 10 Holdings %
Top 10 Hldgs %
89.99%
Holding
33
New
1
Increased
7
Reduced
6
Closed
7
Top Buys
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
$9.06M |
| 2 |
Atea Pharmaceuticals
AVIR
|
$7.69M |
| 3 |
TECX
Tectonic Therapeutic, Inc. Common Stock
TECX
|
$5.77M |
| 4 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$934K |
| 5 |
VistaGen Therapeutics
VTGN
|
$524K |
Top Sells
| 1 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
$6.86M |
| 2 |
Abercrombie & Fitch
ANF
|
$4.43M |
| 3 |
Quince Therapeutics
QNCX
|
$2.12M |
| 4 |
Adverum Biotechnologies
ADVM
|
$1.86M |
| 5 |
Tilly's
TLYS
|
$1.34M |
Sector Composition
| 1 | Healthcare | 55.95% |
| 2 | Technology | 2.05% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$56.1B
| $27.2M | 24.96% | 270,000 +90,000 | +50% | +$9.06M |
|
2
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $18.4M | 16.86% | 200,000 | – | – |
|
|
3
Atea Pharmaceuticals
AVIR
$267M
| $14.4M | 13.22% | 4,800,000 +2,563,761 | +115% | +$7.69M |
|
|
CYT
4
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $9.23M | 8.48% | 3,250,008 +8 | +0% | +$23 |
|
|
TECX
5
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $6.16M | 5.66% | 4,001,627 +3,745,350 | +1,461% | +$5.77M |
|
|
6
Adverum Biotechnologies
ADVM
$64.6M
| $5.87M | 5.39% | 3,915,000 -1,242,179 | -24% | -$1.86M |
|
7
Tourmaline Bio
TRML
$601M
| $5.62M | 5.16% | 2,000,000 | – | – |
|
|
CLYM
8
Climb Bio, Inc. Common Stock
CLYM
$151M
| $5.1M | 4.68% | 1,938,263 +355,093 | +22% | +$934K |
|
9
Athira Pharma
ATHA
$15.3M
| $3.44M | 3.16% | 1,704,362 -160,545 | -9% | -$324K |
|
10
Astrotech Corp
ASTC
$8.72M
| $2.23M | 2.04% | 220,410 | – | – |
|
11
Oramed Pharmaceuticals
ORMP
$90.2M
| $2.04M | 1.87% | 781,292 -68,708 | -8% | -$179K |
|
|
ORKA
12
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $1.42M | 1.3% | 706,930 | – | – |
|
13
Passage Bio
PASG
$22.7M
| $1.35M | 1.24% | 2,058,767 | – | – |
|
14
Forte Biosciences
FBRX
$137M
| $1.17M | 1.07% | 1,761,702 +26,627 | +2% | +$17.6K |
|
15
Milestone Pharmaceuticals
MIST
$156M
| $845K | 0.78% | 272,500 | – | – |
|
16
Enliven Therapeutics
ELVN
$1.2B
| $683K | 0.63% | 50,000 -24,232 | -33% | -$331K |
|
17
Retractable Technologies
RVP
$25.1M
| $595K | 0.55% | 499,959 -168,616 | -25% | -$201K |
|
18
Verrica Pharmaceuticals
VRCA
$52.8M
| $583K | 0.54% | 150,000 | – | – |
|
|
19
VistaGen Therapeutics
VTGN
$102M
| $524K | 0.48% | +100,000 | New | +$524K |
|
20
Lisata Therapeutics
LSTA
$19.9M
| $522K | 0.48% | 243,839 | – | – |
|
21
NextCure
NXTC
$13.5M
| $395K | 0.36% | 306,465 | – | – |
|
22
Neurogene
NGNE
$264M
| $390K | 0.36% | 98,664 +74,915 | +315% | +$296K |
|
23
CalciMedica
CALC
$37.7M
| $236K | 0.22% | 88,781 | – | – |
|
|
RAIN
24
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $62.8K | 0.06% | 72,926 | – | – |
|
25
Surrozen
SRZN
$104M
| $43.7K | 0.04% | 89,271 -1,369,813 | -94% | -$671K |
|